Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | CMO & Sr VP, Clinical Dev. | January 31, 2025 | January 31, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date January 31, 2025 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.79 · Expires 2035-01-30 | Direct | 110,000 |
Reported balance
After 2025-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-31 · Grant · Acquired 110,000 · Balance 110,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2025 Filed Jan 31, 2025 16:38 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002429 · rdgdoc.xml · derivative · entry 1 Huhn Stephen L. · CIK 0001863904 · CMO & Sr VP, Clinical Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-01-30 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 18:03 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 12,800 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-24-026903 · rdgdoc.xml · derivative · entry 2 Huhn Stephen L. · CIK 0001863904 · CMO & Sr VP, Clinical Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,394 Underlying: Class A Common Stock · 12,800 shares Expires 2030-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan. The option is fully vested. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 18:03 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 12,800 | $1.01 | $12,928.00 |
DisclosureSEC source: 0001437749-24-026903 · rdgdoc.xml · nonDerivative · entry 1 Huhn Stephen L. · CIK 0001863904 · CMO & Sr VP, Clinical Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of Class A Common Stock. Read SEC document |
| May 24, 2024 Filed May 29, 2024 17:56 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018623 · rdgdoc.xml · derivative · entry 1 Huhn Stephen L. · CIK 0001863904 · CMO & Sr VP, Clinical Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.